Taxane

Researchers from RWJBarnabas Health and Rutgers Cancer Institute will showcase 45 innovative cancer studies at the 2025 ASCO Annual Meeting, highlighting advances across multiple tumor types and treatment approaches.

A comprehensive review reveals that exercise interventions, particularly aerobic activities, may significantly improve chemotherapy-induced peripheral neuropathy symptoms in ovarian cancer patients.

Adjuvant anthracycline- plus taxane-based chemotherapy (T-AC) improves survival outcomes in high-risk, early-stage, hormone receptor (HR)-positive, HER2-negative breast cancer patients.

A Phase 3 trial (MK-5684-003) is underway to evaluate opevesostat, a CYP11A1 inhibitor, against next-generation hormonal agent (NHA) switch in mCRPC patients after NHA and taxane-based chemotherapy.

Trastuzumab duocarmazine significantly improves progression-free survival compared to physician's choice in pretreated HER2-positive metastatic breast cancer patients.